Live Trading News — Latest Market Updates
KXCO Three for Three on FDA Decisions
KXCO's model books held Inovio's INO-3107, and the FDA approved it. They held neither ivonescimab nor deramiocel, and the FDA refused both. Both books are ahead of the S&P 500, the Nasdaq, the Dow and the biotech industry.
The FDA has ruled on three drugs on KXCO's FDA board since we set our model books in October 2026, and all three are wins for the books. They held INO-3107, and the FDA approved it on 30 October. They held neither ivonescimab nor deramiocel, and the FDA refused both. Per the books' public ledger and Yahoo Finance closes, from 14 October to 20 November 2026, Book 1 rose 0.9% and Book 2 rose 2.1%, while the S&P 500 fell 10.5%, the Nasdaq 15.3%, the Dow 6.7% and XBI 4.5%.

The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
- KXCO's FDA Ontology Is Two for Two on FDA Decisions
- Quantum Computing in November 2026: The Cost of Breaking Your Keys Keeps Falling
- The Week Ahead on Wall Street, 16 November 2026: Look for the Bounce
- KXCO's FDA Ontology Ranked INO-3107 First. Its Two Published Books Beat XBI.
- AI Is Still a Buy: The Noise Will Not Stop the Build-Out
- Jensen Huang, Nvidia and the Morality Game America Plays With Itself
Shayne Heffernan

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
Stocks

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
FX

The Week Ahead on Wall Street, 16 November 2026: Look for the Bounce
NVIDIA reports on Tuesday 17 November 2026, its first results since Jensen Huang resigned, and I expect the stock and the AI market to bounce. NVIDIA closed at $162.85 on 13 November 2026, 31.93% below its record, while the semiconductor index rose 8.05% on the week. The calendar leans to currencies, with the yen near 160 after briefly crossing it, and the US publishes retail sales, housing starts, jobless claims and the Fed's minutes. Follow them on the Live Trading News trading page.
Biotech

The Week Ahead on Wall Street, 16 November 2026: Look for the Bounce
NVIDIA reports on Tuesday 17 November 2026, its first results since Jensen Huang resigned, and I expect the stock and the AI market to bounce. NVIDIA closed at $162.85 on 13 November 2026, 31.93% below its record, while the semiconductor index rose 8.05% on the week. The calendar leans to currencies, with the yen near 160 after briefly crossing it, and the US publishes retail sales, housing starts, jobless claims and the Fed's minutes. Follow them on the Live Trading News trading page.
Quantum

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
AI

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
Blockchain

AI Stocks, Week of 1 November 2026: Seven Buys and the Ontology Behind Them
Shayne Heffernan rates seven AI stocks buys for the week of 1 November 2026: Nvidia, Broadcom, TSMC, Microsoft, Oracle, Palantir and ASML. The latest results put the contracted backlog of the four largest cloud sellers at about $2.48 trillion, and Amazon, Alphabet, Microsoft and Meta plan about $720 billion to $740 billion of capital spending in 2026. Every call links to KXCO's AI ontology, updated on 1 November with the quarter's results, power and grid data and new defence contracts.
KXCO

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
Longevity

KXCO's FDA Ontology Is Two for Two on FDA Decisions
The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.
Travel

How to Retire and Grow Your Own Food
A full guide to retiring onto land that feeds you. USDA puts Ozark pasture at $3,500 an acre. Eurostat puts Latvian arable at 4,825 euro a hectare, though Bulgaria and Romania bar non-EU buyers outright. Thailand will not sell a foreigner an acre at any price. Inside: what the build really costs, which crops pay the bills, how many eggs a hen gives, how to can without killing anyone, a 36 month startup sequence, and how to check every number here.































